Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ocumetics Technology Corp ( (TSE:OTC) ) has issued an announcement.
Ocumetics Technology Corp., a Canadian developer of advanced intraocular lenses and other ophthalmic innovations, is in a first-in-human early feasibility study for a lens designed to sit in the eye’s natural lens compartment. The device is intended to use the eye’s own muscle activity to provide clear vision at all distances, targeting a future where many patients may no longer need corrective eyewear.
The company has appointed veteran capital markets and resource-sector executive Raymond Marks to its board of directors. Marks, who helped secure initial financing for Ocumetics’ public listing and has raised more than $16 million for previous ventures, is expected to bolster the company’s fundraising capabilities as it advances its clinical and development programs.
The most recent analyst rating on (TSE:OTC) stock is a Hold with a C$0.53 price target. To see the full list of analyst forecasts on Ocumetics Technology Corp stock, see the TSE:OTC Stock Forecast page.
Spark’s Take on TSE:OTC Stock
According to Spark, TipRanks’ AI Analyst, TSE:OTC is a Neutral.
The score is primarily held down by very weak financial performance (no revenue, ongoing losses, negative equity, and persistent cash burn). Technicals also remain bearish with the stock trading below key moving averages and negative MACD, despite oversold readings. Positive corporate updates around clinical progress and financing provide some support but are not yet reflected in operating fundamentals.
To see Spark’s full report on TSE:OTC stock, click here.
More about Ocumetics Technology Corp
Ocumetics Technology Corp. is a Canadian research and product development company focused on next-generation ophthalmic technology and advanced vision correction solutions. The firm is developing state-of-the-art intraocular lenses and other vision-enhancing technologies aimed at transforming ophthalmology and potentially eliminating the need for glasses or contact lenses.
Average Trading Volume: 36,597
Technical Sentiment Signal: Hold
Current Market Cap: C$24.71M
For an in-depth examination of OTC stock, go to TipRanks’ Overview page.